NCT05785117

Vagal Nerve Stimulation as Therapeutic Approach on Metabolic Syndrome

Completed NA Last updated 14 August 2024

What this trial tests

NA trial testing Vagal Stimulation in Metabolic Syndrome in 70 participants. Completed in 30 May 2023.

Timeline

1 March 2023

Primary endpoint
30 April 2023

30 May 2023

Quick facts

Lead sponsor	Rana Elbanna
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	single group
Masking	single
Primary purpose	treatment
Enrollment	70
Start date	1 March 2023
Primary completion	30 April 2023
Estimated completion	30 May 2023
Sites	1 location across Egypt

Drugs / interventions tested

• Vagal Stimulation
• Circuit training program

Conditions studied

• Metabolic Syndrome — all drugs for Metabolic Syndrome →

Sponsor

Rana Elbanna

Who can join

Adults 45 to 55, male only, with Metabolic Syndrome. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Participants were randomly assigned to two groups prior to their second visit: the Vagus nerve stimulation group (VNS) and the circuit training program. The randomization processes were conducted in Excel utilizing a random-number generator. Prior to the second visit, each participants' target exercise heart rate ranges were determined. Vagus nerve stimulation group(VNS) Patients rested on their sides in a sitting position. Following regular disinfection of the stimulation locations, ear clips were placed in the ear region (auricular concha) at the stimulation site. The training regimen included ten different forms of resistance and aerobic exercises.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

1. Effect of adding noninvasive auricular Vagal nerve stimulation to exercise program on emotional eating and stress responsiveness in patient with metabolic syndrome.
   Elbanna RHM, Elabd SOA, Saleh MSM, Alghitany SIA. · · 2025 · PMID 40382680 · DOI 10.1080/09638288.2025.2506824